Alpelisib - Latest Advances

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Journal: Journal of medicinal chemistry

Published: November 17, 2025

A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes.

Journal: Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer

Published: November 10, 2025

Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review.

Journal: Journal of cutaneous medicine and surgery

Published: October 31, 2025

Erratum to "Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer" [Biomed. Pharmacother. 192 (2025), 118620].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 17, 2025

Adult-Onset Cervical Lymphatic Malformation: A Case Report.

Journal: Cureus

Published: September 30, 2025

USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.

Journal: The Journal of clinical investigation

Published: September 24, 2025

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer.

Journal: JCO precision oncology

Published: September 17, 2025

Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 08, 2025

From Haemorrhagic Shock to Years of Survival: A Case Report of PIK3CA-Mutated Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer With Satellite Lesions.

Journal: Cureus

Published: September 08, 2025

Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.

Journal: Advances in biological regulation

Published: September 04, 2025

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.

Journal: Annual review of pharmacology and toxicology

Published: August 19, 2025

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.

Journal: Cancers

Published: August 08, 2025

Filters

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes.

A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes.

Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review.

Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review.

Erratum to "Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer" [Biomed. Pharmacother. 192 (2025), 118620].

Erratum to "Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer" [Biomed. Pharmacother. 192 (2025), 118620].

Adult-Onset Cervical Lymphatic Malformation: A Case Report.

Adult-Onset Cervical Lymphatic Malformation: A Case Report.

USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.

USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer.

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer.

Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.

Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.

From Haemorrhagic Shock to Years of Survival: A Case Report of PIK3CA-Mutated Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer With Satellite Lesions.

From Haemorrhagic Shock to Years of Survival: A Case Report of PIK3CA-Mutated Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer With Satellite Lesions.

Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.

Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers.

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.